Steve Soper,
Foundation Distinguished Professor, Director, Center of BioModular Multi-Scale System for Precision Medicine,
The University of Kansas
Prof. Soper is currently a Foundation Distinguished Professor in Chemistry and Mechanical Engineering at the University of Kansas, Lawrence. Prof. Soper also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor. He is also serving as a Science Advisor for a number of major worldwide companies. Prof. Soper is currently on the Editorial Board for Scientific Reports and Journal of Micro- and Nanosystems.
As a result of his efforts, Prof. Soper has secured extramural funding totaling >$103M and has published over 265 peer-reviewed manuscripts (h index = 71) and is the author of 20 patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of circulating tumor cells. His list of awards includes Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award for Microchemistry, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer in the state of Louisiana in 2001. Finally, Prof. Soper has granted 60 PhDs and 6 MS degrees to students under his mentorship. He currently heads a group of 20 researchers.
Affinity Selection of Extracellular Vesicles using Plastic-based Microfluidic Devices for the Management of Different Diseases
Monday, 13 December 2021 at 15:00
Add to Calendar ▼2021-12-13 15:00:002021-12-13 16:00:00Europe/LondonAffinity Selection of Extracellular Vesicles using Plastic-based Microfluidic Devices for the Management of Different DiseasesExtracellular Vesicles (EVs): Technologies and Biological Investigations in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
We have been developing tools for the diagnosis of a variety of
diseases. The commonality in these tools is that they consist of
microfluidic devices made from plastics via injection molding. Thus, our
tools can be mass produced at low-cost to facilitate bench-to-bed side
transition and point-of-care testing (PoCT). We have also been
generating novel assays focused on using liquid biopsy samples that are
enabled using microfluidics. In this presentation, I will talk about the
evolution of our fabrication efforts of plastic-based microfluidic and
nanofluidic devices as well their surface modification to make the
devices biocompatible for in vitro diagnostics. One tool that we have
generated is a plastic device (38 × 42 mm) that consists of 1.5M
pillars, which are surface decorated with affinity agents targeting
certain disease-associated extracellular vesicles (EVs). The affinity
agents are covalently attached to the surface of the microfluidic device
using a bifunctional linker, which consists of a coumarin moiety to
allow for the photolytic release of the captured EVs using a blue-light
LED to minimize photodamage to the EVs’ molecular cargo. We have also
developed a high-throughput nano-Coulter counter (nCC) made from a
plastic via injection molding for the counting of captured EVs from
clinical samples to allow their enumeration. The nCC consists of
multiple pores that are ~350 nm to allow for high throughput counting
with exquisite LODs (500 EVs/mL). In this presentation, I will discuss
the utility of these microfluidic and nanofluidic devices in several
diseases, for example, using EVs as a source of mRNAs for molecular
sub-typing of breast cancer patients. EVs were affinity selected from
breast-cancer patients’ plasma by searching for both epithelial and
mesenchymal expressing EVs to allow for highly efficient sub-typing
using the PAM50 gene panel. In an addition, the microfluidic and
nanofluidic devices were integrated into a single platform
(modular-based system) for PoCT to screen for early stage ovarian
cancer. Affinity probes were used to target EVs specifically generated
from tumor cells that signal early-stage ovarian cancer disease with the
nCC used for enumerating the number of EVs captured. Finally, the
modular system was used for the detection of COVID-19 at the PoC by
affinity selecting SARS-CoV-2 viral particles. The integrated system
could process saliva samples to search for the viral particles and count
them in <20 min.
Add to Calendar ▼2021-12-13 00:00:002021-12-15 00:00:00Europe/LondonExtracellular Vesicles (EVs): Technologies and Biological InvestigationsExtracellular Vesicles (EVs): Technologies and Biological Investigations in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2021-12-13 15:00:002021-12-13 16:00:00Europe/LondonAffinity Selection of Extracellular Vesicles using Plastic-based Microfluidic Devices for the Management of Different DiseasesExtracellular Vesicles (EVs): Technologies and Biological Investigations in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
